Peritoneo-caval shunt after reinfusion treatment with cell-free and concentrated autogenous ascitic fluid in patients with intractable ascites.

スポンサーリンク

概要

• 論文の詳細を見る

• Intravenous reinjection of ascitic fluid after its filtration and concentration was performed to prevent pulmonary edema in patients with intractable ascites resistant to medical therapy. After reduction of the ascitic fluid volume, a peritoneo-caval shunt was created, using a LeVeen's pump, such that the ascitic volume could be semipermanently reduced.Six patients including 4 males and 2 females, whose ages ranging from 42 to 65 years old (mean age: 55.3 years old), were evaluated with regard to the effects of this mode of combination therapy. Ascites resulted from chronic renal failure in 2 patients, from liver cirrhosis in 2, from gastric cancer in 1, and from uterine cancer in 1.The ascites was treated by a Plascit-01 system (Asahi Medical Co.). Filtration was done using an AHF-MA filtration system and subsequent concentration was achieved with an AHF-UN concentration system. Two to 4 liters of the recovered ascites were filtered and concentrated to 100-200 mililiters, and intravenously reinjected into the patients in 4-7 divided doses (mean number of doses: 4.8). Subsequently, an ascites shunt was created between the peritoneal cavity and the superior vena cava.Of the 6 patients evaluated, 5 died. Survival was prolonged from 1 to 3.5 years in our patients (mean duration of prolonged survival: 2.3 years) with the use of these combined methods. Symptoms were also ameliorated during the period of prolonged survival. The one remaining patient is presently on hemodialytic therapy and in stable clinical condition 4.2 years after undergoing combined treatment. No complications were noted in our patients while they were being treated with either the intravenous reinjection of ascitic fluid or the shunt creation procedure.Our findings showed that the combination of intravenous reinjection after filtration and concentration of ascites and creation of a peritoneo-caval shunt is more effective and safer than either one of the 2 forms of treatment used alone for treatment of patients with intractable ascites.

• 社団法人 日本透析医学会の論文

社団法人 日本透析医学会 | 論文

• 4．血液浄化療法の生体適合性と腎性貧血
• PD-HD併用療法においての腎機能保護の可能性 : 第51回日本透析医学会ワークショップより
• 腹部大動脈人工血管の仮性動脈瘤破裂，および右大腿回旋動脈の仮性動脈瘤破裂をきたした血液透析患者の1例
• 5．透析患者のインスリン抵抗性と腎性貧血
• 摘出腫瘤の病理組織標本所見より頸椎腫瘍状石灰沈着症 (cervical tumoral calcinosis) と診断し得た維持透析患者の1例

もっと見る

スポンサーリンク